Glioblastoma (GBM) is a common and aggressive cancer that starts within the brain. So far, patients with GBM who undergo immunotherapy are not responding well to the treatment and poor outcomes remain. Here, speaking at the 2017 National Cancer Research Institute (NCRI) Conference, held in Liverpool, UK, Pakawat Chongsathidkiet, MD, of Duke University, Durham, NC, explains a new phenomenon that may be responsible for the lack of responsiveness to immunotherapy in patients with GBM and his hopes of improving the efficacy of this treatment.
Bone marrow T-cell sequestration: a novel phenomenon in glioblastoma
